Takeda Pharmaceutical (TAK) stock
NYSE
As of the Nov 17, 2026 close (U.S. Eastern)
- Market cap
- $69.1B
- Date not confirmed
- P/E
- -74.42x
- Latest fiscal year
- P/B
- 1.52x
- Latest reported equity
- P/S
- 2.51x
- Latest fiscal year
- ROE
- -2.0%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
The price date behind the multiples is not confirmed; they may differ from the current price.
- Market cap
- $69.1B
- Date not confirmed
- P/E
- -74.42x
- Latest fiscal year
- P/B
- 1.52x
- Latest reported equity
- P/S
- 2.51x
- Latest fiscal year
- ROE
- -2.0%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
The price date behind the multiples is not confirmed; they may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · not confirmed · Financial period · Latest fiscal year
Latest fiscal-year financials · Computed in-house by ChickenStock
P/E
-74.42x
Net loss — not comparable
P/B
1.52x
P/S
2.51x
Earnings and dividend metrics▾
Earnings
EPS
-$0.60
Earnings per share
BPS
$29.11
Book value per share
ROE
-2.0%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $0.60 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $29.11 of net assets.
- ROE — shareholder equity shrank by 2.0% over a year.
Dividends
Dividend per share
$1.22
Payout ratio
-205.0%
Dividend per share and payout ratio are for fiscal 2026.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $122.00 before tax.
- Payout ratio — -205.0% of earnings was paid out as dividends.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
Recent results in a standard quarterly format were not found in SEC filings.
Some foreign companies file only annual or current reports, so quarterly figures may be missing.
See recent SEC filings →Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Platford Giles RichardPresident, IBU · Nov 4, 2026Open-market sale55,617 shares · $1.2MAvg. price $20.9270,253 shares held after
- Bitetti Teresa MariePresident, OBU · Nov 2, 2026Open-market sale46,609 shares · $974KAvg. price $20.89214,501 shares held after
- Duprey Lauren RusckowskiChief Transformation Officer · Sep 14, 2026Open-market sale34,535 shares · $640KAvg. price $18.54191,522 shares held after
- Plump Andrew StewartPresident, R&D · Sep 2, 2026Open-market sale116,191 shares · $2.1MAvg. price $18.49145,465 shares held after
- Plump Andrew StewartPresident, R&D · Aug 19, 2026Open-market sale19,651 shares · $363KAvg. price $18.49261,656 shares held after
- Greenway Nicola Deidre PetalChief Human Resources Officer · Aug 18, 2026Open-market sale12,980 shares · $235KAvg. price $18.113940,049 shares held after
- Shannon Elaine MaryPres., Global Supply & Quality · Aug 11, 2026Open-market sale20,363 shares · $357KAvg. price $17.5567,311 shares held after
- Plump Andrew StewartPresident, R&D · Aug 10, 2026Open-market sale165,393 shares · $2.8MAvg. price $17.1766,569 shares held after
- Kim Julie So-YoungPresident and CEO · Aug 10, 2026Open-market sale89,090 shares · $1.5MAvg. price $17.1391,489 shares held after
- Bitetti Teresa MariePresident, OBU · Aug 10, 2026Open-market sale50,012 shares · $855KAvg. price $17.1252,010 shares held after
- Duprey Lauren RusckowskiChief Transformation Officer · Aug 10, 2026Open-market sale47,586 shares · $814KAvg. price $17.1226,057 shares held after
- Greenway Nicola Deidre PetalChief Human Resources Officer · Aug 10, 2026Open-market sale41,377 shares · $722KAvg. price $17.44
Show 3 price lots
- 33,628 shares × $17.5067$589K
- 6,774 shares × $17.1$116K
- 975 shares × $17.5$17K
- Platford Giles RichardPresident, IBU · Aug 10, 2026Open-market sale31,083 shares · $532KAvg. price $17.1315,838 shares held after
- Furney Natalie Anne MarieGlobal General Counsel · Aug 10, 2026Open-market sale30,868 shares · $528KAvg. price $17.1204,298 shares held after
- Ricci GabrieleChief Data & Tech. Officer · Aug 10, 2026Open-market sale25,088 shares · $429KAvg. price $17.1171,654 shares held after
- Pignagnoli Agosti MarcelloHead, Strat. & Port. Dev · Aug 10, 2026Open-market sale22,957 shares · $393KAvg. price $17.1176,977 shares held after
- Pacheco Rhonda JanicePresident, U.S. Business Unit · Aug 10, 2026Open-market sale16,901 shares · $289KAvg. price $17.1182,507 shares held after
- Farajallah Awny Samaan BotrosChief Medical Officer · Aug 10, 2026Open-market sale14,006 shares · $240KAvg. price $17.1116,177 shares held after
- Ibrahim Ramy Riad AhmedPresident, PDT BU · Aug 10, 2026Open-market sale7,277 shares · $124KAvg. price $17.1102,588 shares held after
- Shannon Elaine MaryPres., Global Supply & Quality · Aug 10, 2026Open-market sale3,978 shares · $68KAvg. price $17.163,333 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Takeda Pharmaceutical (TAK) stock information
NYSE
Takeda Pharmaceutical (TAK) is listed on NYSE. Its market capitalization is about $69.1B. On trailing-twelve-month earnings the P/E ratio is -74.42, and the P/B ratio is 1.52. Return on equity is -2%. These figures are computed in-house from official filings and are reference information only.
Takeda Pharmaceutical — frequently asked questions
- What is the P/E ratio of Takeda Pharmaceutical (TAK)?
- On a trailing-twelve-month basis, TAK trades at a P/E ratio of -74.42. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Takeda Pharmaceutical?
- TAK has a market capitalization of about $69.1B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.